Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Biotest Aktiengesellschaft

Healthcare US BIESF

NoneUSD
0.00(0%)

Last update at 2025-07-17T13:08:57.174531Z

Day Range

--
LowHigh

52 Week Range

34.6041.45
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap1560.87M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield0.11%
  • EBITDA158.18M
  • Revenue TTM655.60M
  • Revenue Per Share TTM13.04
  • Gross Profit TTM 80.70M
  • Diluted EPS TTM-0.3

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -30.80000M -62.60000M -30.00000M -1.30000M -6.00000M
Minority interest - - - 0.00000M 0.20M
Net income -31.70000M -63.40000M -31.40000M -4.70000M 181.70M
Selling general administrative 31.70M 30.10M 28.20M 31.30M 31.60M
Selling and marketing expenses 49.00M 51.10M 50.20M 49.60M 51.60M
Gross profit 124.90M 80.70M 130.10M 128.80M 134.80M
Reconciled depreciation 35.80M 31.10M 29.60M 31.70M 24.70M
Ebit -13.00000M -51.80000M -13.20000M -6.50000M 1.90M
Ebitda 22.80M -20.70000M 16.40M 25.20M 26.60M
Depreciation and amortization 35.80M 31.10M 29.60M 31.70M 24.70M
Non operating income net other - - - - -
Operating income -16.60000M -47.10000M -1.30000M -1.20000M 10.60M
Other operating expenses 524.60M 567.70M 486.70M 425.80M 397.80M
Interest expense 19.70M 13.20M 14.20M 10.70M 10.90M
Tax provision 0.80M 0.70M 1.40M 3.40M 6.90M
Interest income 0.80M 0.20M 1.20M 1.20M 3.30M
Net interest income -22.80000M -15.70000M -15.80000M -10.70000M -16.50000M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 0.80M 0.70M 1.40M 3.40M 6.90M
Total revenue 516.10M 515.60M 484.20M 419.10M 400.30M
Total operating expenses 133.40M 132.80M 132.60M 135.50M 132.30M
Cost of revenue 391.20M 434.90M 354.10M 290.30M 265.50M
Total other income expense net -14.20000M -15.50000M -28.70000M -0.10000M -16.60000M
Discontinued operations - - - - 194.60M
Net income from continuing ops -31.70000M -63.40000M -31.40000M -4.70000M -12.90000M
Net income applicable to common shares - -63.40000M -31.40000M -5.10000M 181.70M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1203.00M 1104.20M 1131.30M 1108.40M 1042.30M
Intangible assets 9.20M 4.10M 6.90M 6.60M 9.20M
Earning assets - - - - -
Other current assets 3.10M 3.10M 1.20M 1.40M 0.40M
Total liab 831.90M 723.80M 689.70M 631.50M 547.10M
Total stockholder equity 371.10M 380.40M 441.60M 476.90M 495.00M
Deferred long term liab - - - - 0.00000M
Other current liab 69.70M 61.20M 55.70M 55.50M 51.50M
Common stock 39.60M 39.60M 39.60M 39.60M 39.60M
Capital stock 39.60M 39.60M 39.60M 39.60M 39.60M
Retained earnings 111.70M 121.00M 182.20M 217.50M 235.60M
Other liab - 121.00M 121.60M 113.60M 92.80M
Good will 7.20M 7.10M 7.10M 7.20M 7.20M
Other assets - 90.40M 249.70M 251.60M 227.20M
Cash 116.60M 104.40M 71.30M 60.80M 61.90M
Cash and equivalents - - - - -
Total current liabilities 130.20M 106.40M 105.60M 115.00M 125.60M
Current deferred revenue 64.80M 56.90M 49.80M 47.80M 46.40M
Net debt 457.70M 391.90M 397.80M 348.80M 267.50M
Short term debt 9.40M 6.40M 7.90M 7.30M 0.70M
Short long term debt 4.80M 29.50M 3.50M 3.30M 0.50M
Short long term debt total 574.30M 496.30M 469.10M 409.60M 329.40M
Other stockholder equity 219.80M 219.80M 219.80M 219.80M 200.00M
Property plant equipment - 476.70M 311.30M 320.30M 307.20M
Total current assets 619.40M 522.20M 556.30M 522.80M 495.10M
Long term investments - - - - 1.90M
Net tangible assets - 370.00M 430.20M 465.10M 484.10M
Short term investments 20.00M 13.10M 17.90M 24.90M 44.20M
Net receivables 185.90M 157.00M 175.80M 155.60M 180.30M
Long term debt 540.50M 473.40M 438.20M 379.60M 325.60M
Inventory 293.80M 244.60M 290.10M 280.10M 208.30M
Accounts payable 51.10M 38.80M 42.00M 52.20M 73.40M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - -
Non currrent assets other 33.60M 19.20M 18.60M 38.20M 103.60M
Deferred long term asset charges - - - - -
Non current assets total 583.60M 582.00M 575.00M 585.60M 547.20M
Capital lease obligations 29.00M 26.80M 27.40M 26.70M 3.30M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -37.00000M -5.50000M 11.50M 18.40M 18.40M
Change to liabilities - 1.90M -4.90000M -16.20000M 12.00M
Total cashflows from investing activities - -23.40000M -14.60000M -8.00000M 200.80M
Net borrowings - 19.80M 42.70M 38.60M -95.20000M
Total cash from financing activities 89.60M 22.60M 42.00M 40.50M -111.20000M
Change to operating activities - -4.20000M 2.00M 1.20M -0.80000M
Net income 31.70M -63.40000M -30.00000M -1.30000M -6.00000M
Change in cash 12.20M 33.10M 10.50M -1.10000M 39.60M
Begin period cash flow 104.40M 71.30M 60.80M 61.90M 22.30M
End period cash flow 116.60M 104.40M 71.30M 60.80M 61.90M
Total cash from operating activities -40.50000M 33.90M -16.70000M -33.60000M -50.00000M
Issuance of capital stock - - - - -
Depreciation 35.80M 31.10M 29.60M 31.70M 24.70M
Other cashflows from investing activities - - 0.80M 0.80M 255.40M
Dividends paid -0.80000M -0.80000M -0.80000M -0.80000M 0.80M
Change to inventory -76.10000M 23.80M -29.90000M -44.30000M -90.70000M
Change to account receivables - - - - 0.00000M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities 90.40M 23.40M 45.30M 45.30M 484.80M
Change to netincome - 44.70M 17.80M -1.30000M -176.80000M
Capital expenditures 29.30M 18.20M 27.00M 34.10M 54.60M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -45.20000M 21.50M -32.80000M -59.30000M -79.50000M
Stock based compensation - - - - -
Other non cash items -62.80000M 44.70M 16.50M -4.70000M 10.80M
Free cash flow -69.80000M 15.70M -43.70000M -67.70000M -104.60000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIESF
Biotest Aktiengesellschaft		 - -% - - 476.19 2.38 3.44 3.18 16.17
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Biotest Aktiengesellschaft

Landsteinerstrasse 5, Dreieich, Germany, 63303

Key Executives

Name Title Year Born
Dr. Michael Ramroth Chairman of the Management Board, CEO & CFO 1962
Dr. Georg Floß COO & Member of the Board of Management NA
Dr. Jorg Schuttrumpf Chief Scientific Officer & Member of the Management Board 1974
Mr. Peter Janssen COO & Member of Management Board 1967
Dr. Monika Buttkereit Head of Investor Relations NA
Dr. Christina Erb Head of Corp. HR NA
Dr. Katrin Bernöster Head of the Project Management Organisation NA
Mr. Peter Seith Head of Quality Operations NA
Dirk Schuck Member of Supervisory Board 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions